GoodRx Holdings, Inc. (NASDAQ:GDRX) Short Interest Update

GoodRx Holdings, Inc. (NASDAQ:GDRX - Get Free Report) was the target of a significant decline in short interest in November. As of November 15th, there was short interest totalling 7,480,000 shares, a decline of 13.9% from the October 31st total of 8,690,000 shares. Based on an average daily volume of 1,370,000 shares, the days-to-cover ratio is currently 5.5 days. Approximately 8.7% of the shares of the stock are sold short.

GoodRx Trading Down 0.4 %

NASDAQ GDRX traded down $0.02 during trading on Friday, hitting $4.84. The stock had a trading volume of 576,444 shares, compared to its average volume of 2,196,192. GoodRx has a one year low of $4.09 and a one year high of $9.26. The stock has a 50 day simple moving average of $5.98 and a 200 day simple moving average of $7.25. The stock has a market capitalization of $1.84 billion, a price-to-earnings ratio of -161.33, a P/E/G ratio of 3.52 and a beta of 1.39. The company has a debt-to-equity ratio of 0.70, a quick ratio of 5.48 and a current ratio of 5.48.

Analyst Ratings Changes

Several analysts have commented on the stock. Raymond James upgraded shares of GoodRx from an "outperform" rating to a "strong-buy" rating and set a $10.00 price target on the stock in a research note on Friday, August 9th. Citigroup dropped their price target on GoodRx from $10.00 to $7.00 and set a "buy" rating for the company in a research note on Wednesday, November 13th. Barclays reduced their price objective on GoodRx from $10.00 to $6.00 and set an "overweight" rating on the stock in a research note on Monday, November 11th. Royal Bank of Canada reiterated an "outperform" rating and set a $10.00 target price on shares of GoodRx in a research report on Friday, August 16th. Finally, UBS Group reduced their price target on shares of GoodRx from $9.00 to $8.50 and set a "neutral" rating on the stock in a research report on Friday, August 9th. One research analyst has rated the stock with a sell rating, four have given a hold rating, nine have issued a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average price target of $8.86.

Insider Buying and Selling at GoodRx

In other news, major shareholder Equity Vii L.P. Spectrum sold 10,677 shares of the company's stock in a transaction dated Tuesday, September 3rd. The stock was sold at an average price of $7.86, for a total value of $83,921.22. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 4.17% of the company's stock.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in the stock. nVerses Capital LLC purchased a new position in shares of GoodRx during the third quarter valued at $33,000. Plato Investment Management Ltd purchased a new position in GoodRx during the 2nd quarter valued at about $43,000. EP Wealth Advisors LLC bought a new stake in shares of GoodRx in the 3rd quarter valued at about $73,000. Sanctuary Advisors LLC purchased a new stake in shares of GoodRx in the 3rd quarter worth approximately $85,000. Finally, Dark Forest Capital Management LP purchased a new stake in shares of GoodRx in the 2nd quarter worth approximately $86,000. Hedge funds and other institutional investors own 63.77% of the company's stock.

About GoodRx

GoodRx Holdings, Inc, together with its subsidiaries, offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices.